Copanlisib in Patients With Tumors With PIK3CA Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
J. Clin. Oncol 2022 May 10;40(14)1552-1561, S Damodaran, F Zhao, DA Deming, EP Mitchell, JJ Wright, RJ Gray, V Wang, LM McShane, LV Rubinstein, DR Patton, PM Williams, SR Hamilton, JM Suga, BA Conley, CL Arteaga, LN Harris, PJ O'Dwyer, AP Chen, KT FlahertyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.